Convergence Financial LLC Has $2.39 Million Position in Johnson & Johnson $JNJ

Convergence Financial LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 85.8% during the second quarter, HoldingsChannel reports. The fund owned 9,428 shares of the company’s stock after purchasing an additional 4,354 shares during the quarter. Convergence Financial LLC’s holdings in Johnson & Johnson were worth $2,394,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of JNJ. World Investment Advisors lifted its position in shares of Johnson & Johnson by 19.6% in the fourth quarter. World Investment Advisors now owns 161,343 shares of the company’s stock worth $33,390,000 after buying an additional 26,450 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Johnson & Johnson by 0.8% in the 4th quarter. Principal Financial Group Inc. now owns 3,410,177 shares of the company’s stock valued at $705,736,000 after acquiring an additional 28,370 shares in the last quarter. Signal Advisors Wealth LLC raised its stake in shares of Johnson & Johnson by 76.1% in the 1st quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock valued at $3,697,000 after acquiring an additional 6,539 shares in the last quarter. Keybank National Association OH lifted its holdings in Johnson & Johnson by 15.6% in the 4th quarter. Keybank National Association OH now owns 1,354,595 shares of the company’s stock worth $280,334,000 after purchasing an additional 183,181 shares during the last quarter. Finally, Louisiana State Employees Retirement System bought a new stake in Johnson & Johnson during the first quarter worth approximately $30,017,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 63,972 shares of company stock worth $16,245,605 over the last quarter. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $273.28 on Wednesday. The company’s fifty day moving average is $256.59 and its two-hundred day moving average is $243.36. Johnson & Johnson has a 52-week low of $173.33 and a 52-week high of $276.47. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The firm has a market capitalization of $658.58 billion, a price-to-earnings ratio of 31.67, a P/E/G ratio of 2.61 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same quarter in the prior year, the business earned $2.77 earnings per share. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts forecast that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent analyst reports. Guggenheim lifted their price target on shares of Johnson & Johnson from $270.00 to $287.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. TD Cowen upped their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $268.22.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA approved Imaavy (nipocalimab) as the first specifically indicated treatment for warm autoimmune hemolytic anemia (wAIHA) in adults and patients aged 12 and older who currently or previously received corticosteroids. The approval expands J&J’s immunology franchise, addresses an unmet need in a rare, life-threatening disease and provides another potential growth driver for the company’s FcRn antibody platform. FDA approves Imaavy for wAIHA
• Positive Sentiment: Analysts and industry coverage view Imaavy’s approval as progress toward J&J’s goal of achieving approximately $5 billion in peak sales for the drug, although the initial wAIHA patient population is relatively small. The company also received European approval to expand the use of its cancer medicine Tecvayli, broadening its oncology reach. Imaavy and Tecvayli approvals
• Positive Sentiment: J&J’s recent operating momentum remains supportive: its latest quarterly results exceeded revenue and earnings expectations, revenue rose year over year, and management set fiscal 2026 EPS guidance of $11.60-$11.75. J&J pipeline momentum
• Neutral Sentiment: Healthcare stocks have benefited from investors seeking stability amid weakness or elevated valuations in technology shares. J&J’s defensive profile and dividend consistency may support demand, though higher Treasury yields make dividend stocks less relatively attractive. Investors seek stability in J&J
• Neutral Sentiment: J&J shares have risen more than 50% over the past year and are near their 12-month high. Commentary describes the stock as a hold, suggesting that much of the pipeline and earnings optimism may already be reflected in the valuation.
• Negative Sentiment: A Louisiana jury awarded $10 million in a talc-related mesothelioma case, renewing concerns about the company’s asbestos litigation liabilities despite J&J’s proposed multibillion-dollar settlement. FDA approval and talc litigation coverage
• Negative Sentiment: Investors continue to monitor the rapid erosion of Stelara following patent and exclusivity losses, making successful launches such as Imaavy important for replacing declining revenue from older products. J&J patent-cliff comparison

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.